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Abstract
Objective: Research suggests autoimmune processes to be involved in psychiatric disorders. We aimed to address the
prevalence and incidence of autoimmune diseases in a large Finnish patient cohort with anorexia nervosa, bulimia nervosa,
and binge eating disorder.
Methods: Patients (N = 2342) treated at the Eating Disorder Unit of Helsinki University Central Hospital between 1995 and
2010 were compared with general population controls (N = 9368) matched for age, sex, and place of residence. Data of 30
autoimmune diseases from the Hospital Discharge Register from 1969 to 2010 were analyzed using conditional and Poisson
regression models.
Results: Of patients, 8.9% vs. 5.4% of control individuals had been diagnosed with one or more autoimmune disease (OR
1.7, 95% CI 1.5–2.0, P,0.001). The increase in endocrinological diseases (OR 2.4, 95% CI 1.8–3.2, P,0.001) was explained by
type 1 diabetes, whereas Crohn’s disease contributed most to the risk of gastroenterological diseases (OR 1.8, 95% CI 1.4–
2.5, P,0.001). Higher prevalence of autoimmune diseases among patients with eating disorders was not exclusively due to
endocrinological and gastroenterological diseases; when the two categories were excluded, the increase in prevalence was
seen in the patients both before the onset of the eating disorder treatment (OR 1.5, 95% CI 1.1–2.1, P = 0.02) and at the end
of the follow-up (OR 1.4, 95% CI 1.1–1.8, P = 0.01).
Conclusions:We observed an association between eating disorders and several autoimmune diseases with different genetic
backgrounds. Our findings support the link between immune-mediated mechanisms and development of eating disorders.
Future studies are needed to further explore the risk of autoimmune diseases and immunological mechanisms in individuals
with eating disorders and their family members.
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Introduction
Eating disorders are relatively common multifactorial disorders,
the etiology of which appears to be regulated by interplay of
environmental and genetic factors. They are often associated with
substantial somatic morbidity [1–2], since psychological stress
combined with dysregulated eating behavior and subsequent
nutritional disturbances have a potent effect on several organ
systems. On the other hand, the risk of eating disorders has been
shown to be increased in some somatic illnesses [3–5]. Notably,
many of these illnesses, such as type 1 diabetes (T1D) and
inflammatory bowel diseases present autoimmune or autoinflam-
matory etiology.
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A prior autoimmune disease has recently been shown to
increase the risk of mood disorders and schizophrenia [6–7]. In
addition, the risk of both mental disorders increased in a dose
response pattern when autoimmune diseases and infections were
assessed together. The role of autoimmune processes, such as
various pathogens triggering autoantibodies cross-reactive with
neuronal antigens (brain-reactive autoantibodies), has also been
recognized in the pathogenesis of neuropsychiatric disorders [8]
including autism spectrum disorders, obsessive-compulsive disor-
der, tic-disorders, ADHD, post-traumatic stress disorder, and
narcolepsy. Furthermore, pediatric Autoimmune Neuropsychiatric
Disorders Associated with Streptococcal infection (PANDAS)
include anorexia nervosa (AN) [8].
As evidence that autoimmune mechanisms, acting via neu-
roimmunoendocrinological pathways, could be involved in eating
disorders, Fetissov et al. [9] reported that a significant subset of
patients with AN and bulimia nervosa (BN) had autoantibodies
against a-melanocyte-stimulating hormone (a-MSH) and against
adrenocorticotropic hormone (ACTH), which contribute to food
intake and body weight. The authors [10] subsequently observed
that the core psycho-behavioral characteristics of eating disorders
correlated with the levels of autoantibodies against a-MSH;
notably, these correlations were opposite in patients with AN vs.
BN. In an independent sample, decreased levels of immunoglob-
ulins G, M, and A classes of autoantibodies reacting with acyl
ghrelin in AN were also reported [11].
Immune-mediated diseases often show an association with
polymorphisms of genes regulating the function of immune system.
Human leukocyte antigen (HLA) region in chromosome 6
embodies genes, which have been associated with several
autoimmune diseases. Despite genetic factors appearing important
in the etiology of eating disorders, reports of HLA gene
polymorphisms are contradictory. In one study, a higher
frequency of HLA-Bw16 was reported in patients with AN [12],
but the observation was not supported by later reports in AN [13],
or in BN [14].
Prevalence of eating disorders in T1D is reported two-fold
among adolescents in a recent meta-analysis [15]. Utilizing the
current sample, we recently reported a vastly increased T1D-
related mortality in eating disorders [16]. However, studies of the
risk of T1D in individuals with eating disorders are, according to
our knowledge, lacking. Abnormal thyroid values occur in eating
disorders [17], and starvation as well as re-feeding are associated
with altered thyroid function [18]. Crohn’s disease and celiac
disease have been suggested to act as triggers for the development
of eating pathology [19–20], and individuals with celiac disease are
reported to be at increased risk for eating disorders [3].
Unsurprisingly, inflammation of intestinal mucosa may affect
eating patterns; mouse models imply resultant reduced food
intake, where eating is under a specific control of CD4+ T-cells
[21]. Finally, increased prevalence of metabolic syndrome and
eating disorders in individuals with psoriasis has been reported
[22]; the pathogenic mechanism is proposed to relate to immune-
mediated inflammation.
To our knowledge, no large scale reports of the co-morbidity of
autoimmune diseases and eating disorders have been published.
We hypothesized that the risk of autoimmune diseases would be
increased in individuals with eating disorders both prior and after
the onset of the treatment for an eating disorder. Thus, we aimed
to address the incidence and prevalence of autoimmune diseases in
a large Finnish patient cohort of individuals treated for AN, BN,
and binge eating disorder (BED) during 16 years’ period. We
explored the potential associations in three stages; period
prevalence at the onset of the treatment of an eating disorders,
accounting for both prevalent and new onset autoimmune disease
cases for the time before the treatment; incidence after the
treatment onset until the end of the study period to yield the
information of new onset autoimmune diseases and to separate the
potential improved effect of the treatment system to detect the
autoimmune diseases among patients compared to controls
(detection bias); and finally, lifetime prevalence including prevalent
and new onset autoimmune disease cases any time before, during,
or after the treatment until the end of the follow-up.
Materials and Methods
Ethical considerations
Ethical permits were obtained from the Ethics committee of
National Institute of Health and Welfare (Dnro THL/184/
6.02.00/2011). The study was conducted according to the Helsinki
Declaration. Data handling was performed according to the data
protection legislation and the rules of National Institute of Health
and Welfare. All register keeping institutions gave permission to
use their data in scientific research. The authors did not have
access to personal identification data, only research codes were
used in analyses.
Study participants
We identified all patients (N = 2342) treated in the Eating
Disorder Unit at the Helsinki University Central Hospital from
January 1st 1995 to December 30st 2010. For each patient, four
controls (N = 9368) were selected from the Central Population
Register, and matched for age, sex, and place of residence. The
individual follow-up period for incidence of each patient and the
controls started at treatment in the Unit and ended at the first
autoimmune disease hospitalization, or December 31st 2010, or
death (N = 61 patients, N = 69 controls). Only individuals without
autoimmune disease before the start of follow-up were included in
the incidence calculations. We calculated period prevalence of
hospital-treated autoimmune diseases starting at January 1st 1969
until the date of the start of the eating disorder treatment. At the
end of the follow-up, lifetime prevalence was calculated utilizing
Hospital Discharge Register data from January 1st 1969 to
December 31st 2010.
Eating disorder diagnosis was set by the attending psychiatrist at
the Eating Disorder Unit on the patient’s arrival using the ICD-10
criteria [23]. ICD-9 diagnoses given in 1995 were re-coded to
ICD-10 codes. The participants included patients with ICD-10
diagnoses of F50.0, F50.1, F50.2, F50.3, and F50.8 indicating AN,
atypical AN, BN, atypical BN, and BED, respectively. Since
current definitions for eating disorders in DSM-5 [24] have been
relaxed compared to ICD-10 or DSM-IV criteria, we defined AN
and BN as follows: AN included AN and atypical AN. Atypical AN
diagnosis was used for patients in whom some key features of AN,
such as amenorrhea or body weight less than 85% of that
expected, were lacking but who otherwise presented a typical
clinical picture. BN included BN and atypical BN. Atypical BN
diagnosis was used in patients among whom one or two criteria
were lacking, but who otherwise presented a typical clinical
picture. BED, coded as F50.8, ‘Other eating disorder’, was
diagnosed in the Eating Disorder Unit according to the DSM-IV
research criteria.
Assessment of autoimmune disease
The study population was linked to the data of 30 autoimmune
diseases (Table S1) obtained from the Hospital Discharge Register.
It covers all public/private general and psychiatric hospitals,
hospital outpatient clinics and health center inpatient wards.
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Diagnoses were made by the attending physician. The registry
contains hospital identification codes, dates of stay and primary
diagnoses at discharge with up to three subsidiary diagnoses.
Time of the onset of an autoimmune diagnosis was defined as
the first day of the hospital contact leading to the recording in the
Hospital Discharge Register. Each participant could have more
than one autoimmune disease. From 1969 to 1986, ICD-8 was
used as the diagnostic classification, between 1987 and 1995 it was
ICD-9, and since 1996, it was ICD-10.
Statistical analyses
Incidence was analyzed using Poisson regression model where
occurrence of autoimmune disease was used as an outcome
variable and logarithm of cumulated person-years as an offset
term. Results are reported as rate ratios (RR) with 95% confidence
intervals (CI). Period and lifetime prevalences were modeled using
conditional logistic regression model, conditioned with a matching
group; odds ratios (OR) with 95% CI are reported. All calculations
were carried out by R language [25].
Results
General
Characteristics of the study sample are presented in the Table 1.
Participants with BN made up the largest patient group (54.0%),
followed by those with AN (38.8%), and those with BED (7.3%).
The mean age of patients with eating disorders at the start of the
follow-up differed significantly (P,0.001) between diagnostic
groups, patients with AN being the youngest, and those with
BED the oldest. Within eating disorder categories, proportion of
males ranged from 2.3% in BN to 12.9% in BED, being 4.8% in
AN (P,0.001).
Period prevalence of autoimmune diseases until the start
of the follow-up
Until the start of the treatment for an eating disorder, 5.6%
(N = 131) of patients and 2.8% of control individuals (N = 265) had
been diagnosed with one or more autoimmune disease (Table 2).
The risk of prior diagnosis of endocrinological autoimmune
diseases (OR 3.3, 95% CI 2.4–4.6, P,0.001), of gastroenterolog-
ical immune-mediated diseases (OR 2.0, 95% CI 1.3–3.1,
P = 0.002), and of autoimmune diseases combined (OR 2.1 95%
CI 1.7–2.7, P,0.001) was significantly higher among patients than
among matched controls. This was not solely due to endocrino-
logical and gastroenterological diseases; when we excluded these
two categories and analyzed other categories combined, the
difference between the patients and controls remained (OR 1.5,
95% CI 1.1–2.1, P = 0.02).
The higher period prevalence of endocrinological disease was
explained by T1D (2.5% in patients vs. 0.6% in controls; OR 4.3,
95% CI 3.0–6.3), not by thyreotoxicosis (OR 1.3, 95% CI 0.5–1.7)
or autoimmune thyroiditis (OR 1.1, 95% CI 0.2–5.5). When
analyzed separately in AN, BN and BED, the period prevalence of
endocrinological diseases was increased (OR 2.0, 95% CI 1.1–3.6;
OR 4.4, 95% CI 2.8–6.8; OR 3.6, 95% CI 1.4–9.2, respectively).
The increased prevalence of gastroenterological diseases among
patients was largely explained by Crohn’s disease (0.6% in patients
vs. 0.2% in controls; OR 3.1, 95% CI 1.5–6.3), not by celiac
disease (OR 1.4, 95% CI 0.7–3.1), or ulcerative colitis (OR 1.6,
95% CI 0.7–3.2). When analyzed separately in AN, BN and BED,
the period prevalence of gastroenterological diseases was signifi-
cantly increased in AN (OR 2.3, 95% CI 1.1–4.9), but not in BN
(OR 1.6, 95% CI 0.9–2.9) or BED (OR 4.0, 95% CI 1.0–16.0,
P = 0.05).
Table 1. Study sample by diagnostic groups with lifetime prevalence figures of autoimmune diseases covering the time before,
during, and after the treatment for an eating disorder.
Anorexia Nervosa
(N=911)
Bulimia Nervosa
(N=1260)
Binge Eating Disorder
(N=171)
F50.0 Anorexia Nervosa
F50.1 Atypical Anorexia
Nervosa
F50.2 Bulimia Nervosa
F50.3 Atypical Bulimia
Nervosa
F50.8 Other Eating
Disorder, DSM-IV BED
Mean age, years (SD, Range) 23.8 (6.8, 16.0–64.8) 26.2 (7.5, 17.2–64.6) 37.0 (10.6, 17.8–64.2)
Total number participants with ED
(% within a diagnostic group)
Women 867 1231 149
Men 44 (4.8%) 29 (2.3%) 22 (12.9%)
Number (%) of participants ever
treated as inpatient for ED
Women & men 322 (35.3%) 134 (10.6%) 7 (4%)
Participants with ED & with any
autoimmune disease (N, positive/
negative for the autoimmune
disease, % positive)
Women 60/807 (6.9%) 111/1120 (9.0%) 26/123 (17.4%)
Men 4/40 (9.1%) 7/22 (24.1%) 2/20 (9.1%)
Total 64/847 (7.0%) 118/1142 (9.4%) 27/144 (15.8%)
Matched control participants with
any autoimmune disease (N, positive/
negative for the autoimmune disease,
% positive)
Women 166/3302 (4.8%) 288/4636 (5.8%) 36/560 (6.0%)
Men 5/171 (2.8%) 8/108 (6.9%) 6/82 (6.8%)
Total 171/3473 (4.7%) 296/4744 (5.8%) 42/642 (6.1%)
Each participant is presented as one observation, i.e. some autoimmune disease-positive individuals had more than one autoimmune disease. ED, Eating Disorder.
doi:10.1371/journal.pone.0104845.t001
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Table 2. Period prevalences and results from conditional logistic regression models of autoimmune diseases from the start of the
study period until the beginning of the treatment of an eating disorder.
Autoimmune disease category N (Positive/negative for the autoimmune disease, % positive) OR (95% CI) P-value
Any autoimmune disease
Controls 265/9103 (2.8%) reference -
All eating disorders 131/2211 (5.6%) 2.13 (1.71–2.65) ,0.001
Anorexia Nervosa 40/871 (4.4%) 1.76 (1.20–2.59) 0.004
Bulimia Nervosa 71/1189 (5.6%) 2.18 (1.62–2.93) ,0.001
Binge eating Disorder 20/151 (11.7%) 2.79 (1.54–5.03) ,0.001
Endocrinological diseases
Controls 83/9285 (0.89%) reference -
All eating disorders 65/2277 (2.78%) 3.28 (2.35–4.59) ,0.001
Anorexia Nervosa 16/895 (1.76%) 1.95 (1.05–3.59) 0.03
Bulimia Nervosa 41/1219 (3.25%) 4.35 (2.77–6.82) ,0.001
Binge Eating Disorder 8/163 (4.68%) 3.56 (1.37–9.22) 0.009
Gastroenterological diseases
Controls 61/9307 (0.65%) reference -
All eating disorders 30/2312 (1.28%) 1.98 (1.27–3.07) 0.002
Anorexia Nervosa 11/900 (1.21%) 2.32 (1.10–4.87) 0.03
Bulimia Nervosa 15/1245 (1.19%) 1.59 (0.87–2.90) 0.13
Binge Eating Disorder 4/167 (2.34%) 4.00 (1.00–16.0) 0.05
Ocular diseases
Controls 20/9238 (0.21%) reference -
All eating disorders 8/2334 (0.34%) 1.62 (0.71–3.71) 0.26
Anorexia Nervosa 1/910 (0.11%) 0.80 (0.09–6.85) 0.84
Bulimia Nervosa 4/1256 (0.32%) 1.15 (0.37–3.55) 0.81
Binge Eating Disorder 3/168 (1.75%) 12.0 (1.25–115.0) 0.03
Dermatological diseases
Controls 23/9345 (0.25%) reference -
All eating disorders 7/2335 (0.30%) 1.22 (0.52–2.84) 0.65
Anorexia Nervosa 2/909 (0.22%) 0.89 (0.19–4.11) 0.88
Bulimia Nervosa 3/1257 (0.24%) 1.00 (0.28–3.54) 1.00
Binge Eating Disorder 2/169 (1.17%) 4.00 (0.56–28.4) 0.17
Connective tissue diseases
Controls 60/9308 (0.64%) reference -
All eating disorders 22/2320 (0.94%) 1.47 (0.90–2.39) 0.12
Anorexia Nervosa 9/902 (0.99%) 1.71 (0.79–3.74) 0.18
Bulimia Nervosa 6/1254 (0.48%) 0.92 (0.38–2.24) 0.86
Binge Eating Disorder 7/164 (4.09%) 2.15 (0.86–5.40) 0.10
Neurological diseases
Controls 17/9351 (0.18%) reference -
All eating disorders 4/2338 (0.17%) 0.94 (0.32–2.80) 0.91
Anorexia Nervosa 1/910 (0.11%) 1.33 (0.14–12.8) 0.8
Bulimia Nervosa 3/1257 (0.24%) 1.00 (0.28–3.54) 1.00
Binge Eating Disorder 0/171 - -
Hematological diseases
Controls 7/9361 (0.07%) reference -
All eating disorders 3/2339 (0.13%) 1.71 (0.44–6.63) 0.43
Anorexia Nervosa 2/909 (0.22%) 4.00 (0.56–28.4) 0.17
Bulimia Nervosa 1/1259 (0.08%) 0.8 (0.09–6.85) 0.84
Binge Eating Disorder 0/171 - -
For the seven separate autoimmune disease categories presented, each participant counts as maximum one observation per category. For the total figure of any
autoimmune disease, each participant is presented as maximum one observation. Out of all patients and all controls, there was only one patient participant (with
bulimia nervosa) with pulmonary disease (not shown). CI, Confidence Interval; OR, Odds ratio.
doi:10.1371/journal.pone.0104845.t002
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Incidence of autoimmune diseases after the start of the
follow-up
We examined the incidence of new onset autoimmune diseases
beginning at the day that the participants entered to the treatment
for an eating disorder until the end of the study period (Table 3).
After the start of the treatment, a total of 78 new onset
autoimmune disease cases were observed in patients, while 244
new onset cases were observed in control individuals (RR 1.2, 95%
CI 0.9–1.5, P = 0.26). The incidence of gastroenterological
diseases and of dermatological diseases were increased in patients
with eating disorders (RR 1.7, 95% CI 1.1–2.6, and RR 1.8, 95%
CI 1.0–3.2, respectively), and separately in BN (RR 1.9, 95% CI
1.2–3.2, and RR 2.2 95% CI 1.2–4.1). The incidences of ocular
and connective tissue diseases were increased in BED (RR 4.5,
95% CI 1.4–14.6 and RR 3.7, 95% CI 1.2–11.9). We did not find
evidence for differences in the evolution of incidence rate curves of
a composite of all autoimmune diseases between patients and
controls (for hazard curves, see Figure S1), i.e. there was no
evidence for detection bias.
Lifetime prevalence of autoimmune diseases at the end
of the follow-up
In the whole study period, 8.9% (N = 209) of patients and 5.4%
of control individuals (N = 509) had ever been diagnosed with one
or more autoimmune disease (OR 1.7, 95% CI 1.5–2.0, P,0.001)
(Table 4). Of patients with an eating disorders and with at least
one autoimmune disease, 21% (N = 44) had more than one
autoimmune disease, while of controls, the proportion was 15%
(N = 78) (P = 0.08). Among patients with BN, the lifetime
prevalence of autoimmune diseases was higher in men compared
to women (24% vs. 9%, P = 0.006). In other eating disorders or in
control groups, no significant sex-differences were observed.
The lifetime prevalence of endocrinological diseases was
increased in eating disorders (OR 2.4, 95% CI 1.8–3.2, P,
0.001), and when analyzed separately in BN (OR 3.1, 95% CI
2.1–4.5, P,0.001) and in BED (OR 3.3, 95% CI 1.4–7.9,
P = 0.008) (Table 4). The finding was explained by increase in
lifetime prevalence of T1D (2.9% in patients vs. 0.8% in controls,
OR 3.8, 95% CI 2.7–5.3, P,0.001) (Table 5 and Table S2). The
lifetime prevalence of gastroenterological diseases was increased in
eating disorders combined (OR 1.8, 95% CI 1.4–2.5, P,0.001)
and in AN (OR 1.8, 95% CI 1.03–3.0, P = 0.04) and BN (OR 1.8,
95% CI 1.2–2.7, P = 0.004) separately. The finding was largely
explained by the increased prevalence of Crohn’s disease (1.1% in
patients vs. 0.4% in controls, OR 3.1, 95% CI 1.9–5.1, P,0.001)
(Table 5). Also, the lifetime prevalence was increased for ocular
disorders (OR 12.0, 95% CI 2.4–59.5, P = 0.002) in BED. By
disentangling individual autoimmune diseases (Table 5 and Table
S2), the risk of systemic lupus erythematotus (SLE) was increased
in eating disorders (0.3% in patients vs. 0.06% in controls, OR 4.0,
95% CI 1.3–12.4, P = 0.02).
Again, the higher lifetime prevalence of autoimmune diseases
among patients was not solely due to higher prevalences in
endocrinological and gastroenterological diseases; when we
excluded these two categories and analyzed the prevalence of all
other autoimmune diseases combined, the difference between
patients with ED and control individuals remained (OR 1.4, 95%
CI 1.1–1.8, P = 0.01).
Finally, we analyzed combined lifetime prevalence of autoim-
mune diseases with suspected presence of brain-reactive antibodies
(autoimmune thyroiditis, celiac disease, multiple sclerosis, Sjo¨g-
ren’s syndrome, SLE, thyreotoxicosis, T1D) and of all other
autoimmune diseases. OR for the former group was 2.0 (95% CI
1.6–2.5, P,0.0001), and for others it was 1.6 (95% CI 1.4–1.9, P,
0.0001).
Discussion
We observed an increased risk for several autoimmune diseases
among patients with eating disorders supporting the hypothesis of
co-morbidity of these disorders and suggesting that immune-
mediated mechanisms could play a role in the development of
eating disorders. Importantly, our results were not restricted to the
association of T1D with eating disorders as shown in previous
studies. Instead, the association was seen for several autoimmune
diseases with different genetic backgrounds. Our findings thus
suggest that the link between eating disorders and autoimmune
diseases is based on shared immunological mechanisms, rather
than on the shared genetic background, e.g. the shared HLA risk
genotype. In addition, our findings support earlier observations
suggesting that autoimmune processes contribute to the onset and
maintenance of eating disorders, at least in a subpopulation of
patients.
Studies indicate that psychiatric disorders co-exist with inflam-
mation, infections and autoimmune diseases [6–7,26–27], and
shared vulnerability [28–29] underlying many psychiatric disor-
ders suggest that findings from one disorder may be relevant across
categories. Pro-inflammatory cytokines and antibodies/autoanti-
bodies against neuronal antigens could induce changes in
neurotransmitter and neuroendocrine function, which may
subsequently yield psychiatric manifestations. Studies suggest that
pro-inflammatory cytokines may have a role in eating disorders
[30]. However, findings on the circulating cytokines, of which
many decrease food intake, are discrepant. In most longitudinal
studies in AN and BN, their levels return to normal after re-
feeding [30], yet it remains unclear whether the alterations in the
cytokines are due to an eating disorders or due to an underlying
exposure leading to eating disorders. It has also been suggested
[30] that pro-inflammatory cytokines might be overproduced in
specific brain areas and act locally without concomitant increase in
serum or immune production. Indeed, the pro-inflammatory
cytokines are able to activate HPA axis [31], the hyperactivity of
which in eating disorders has been established [32].
Brain-reactive antibodies can be divided to those with direct
effect on the development of the neuropsychiatric symptoms, those
generated secondary to the disease process, and those without
known association with symptoms [33]. Interestingly, a stronger
association with mood disorders was reported among patients with
autoimmune diseases with a suspected presence of brain-reactive
antibodies compared to the patients with other autoimmune
diseases [6]. In our study, there was no significant difference in the
strength of the association between the two groups of autoimmune
diseases. However, unlike in mood disorders, other than primarily
brain-centered mechanisms may more readily be hypothesized to
be involved in the pathogenesis of eating disorders. Chief
candidates include gastrointestinal peptides influencing visceral
organs and central and peripheral nervous systems.
Our findings are supported by the immunological studies
performed in patients with eating disorders [9–11,34], where
autoantibodies against peptides related to appetite-regulation,
stress response, and social-emotional functioning (a-MSH, ACTH,
ghrelin, oxytocin, vasopressin) were detected. The postulated role
of intestinal microflora contributing to the development of cross-
reactive neuronal autoantibodies provides a link between gut and
brain. This link may be particularly relevant in eating disorders
[34] based on the pivotal role of nutrition in the composition of the
gut microbiome. In eating disorders, the core symptom of
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Table 3. Incidence of new onset autoimmune diseases after the start of the treatment for an eating disorder until the end of the
study period.
Autoimmune disease category N Total N Events Person-years (1/1000) Incidence (95% CI) RR (95% CI)
Any autoimmune disease
Controls 9103 244 87.264 3.12 (2.76–3.52) reference
All eating disorders 2211 78 21.242 3.62 (2.86–4.53) 1.16 (0.90–1.49)
Anorexia nervosa 871 24 7.285 3.29 (2.11–4.90) 1.05 (0.69–1.60)
Bulimia Nervosa 1189 47 12.634 3.56 (2.59–4.77) 1.14 (0.83–1.56)
Binge Eating Disorder 151 7 1.323 6.05 (2.61–11.92) 1.93 (0.96–3.90)
Endocrinological diseases
Controls 9285 56 83.262 0.67 (0.51–0.87) reference
All eating disorders 2277 16 20.253 0.79 (0.45–1.28) 1.17 (0.67–2.05)
Anorexia nervosa 895 4 6.999 0.57 (0.16–1.46) 0.85 (0.31–2.43)
Bulimia Nervosa 1219 11 12.055 0.91 (0.46–1.63) 1.36 (0.71–2.59)
Binge Eating Disorder 163 1 1.196 0.84 (0.02–4.66) 1.24 (0.17–8.98)
Gastroenterological diseases
Controls 9307 69 83.677 0.83 (0.64–1.04) reference
All eating disorders 2312 29 20.872 1.39 (0.93–2.00) 1.68 (1.09–2.60)*
Anorexia nervosa 900 9 7.068 1.27 (0.58–2.42) 1.54 (0.77–3.09)
Bulimia Nervosa 1245 20 12.608 1.59 (0.97–2.45) 1.92 (1.17–3.16)*
Binge Eating Disorder 167 0 1.198 0 (0–3.1) 0
Ocular diseases
Controls 9348 43 83.517 0.51 (0.37–0.69) reference
All eating disorders 2334 16 20.710 0.77 (0.44–1.25) 1.50 (0.85–2.66)
Anorexia nervosa 910 6 7.102 0.84 (0.31–1.84) 1.64 (0.70–3.85)
Bulimia Nervosa 1256 7 12.322 0.57 (0.22–1.17) 1.10 (0.50–2.45)
Binge Eating Disorder 168 3 1.283 2.34 (0.48–6.83) 4.54 (1.41–14.64)*
Dermatological diseases
Controls 9345 40 83.410 0.48 (0.34–0.65) reference
All eating disorders 2335 18 20.720 0.87 (0.51–1.37) 1.81 (1.04–3.16)*
Anorexia nervosa 909 3 7.006 0.43 (0.09–1.25) 0.89 (0.28–2.89)
Bulimia Nervosa 1257 13 12.440 1.05 (0.56–1.79) 2.18 (1.17–4.07)*
Binge Eating Disorder 169 2 1.275 1.57 (0.19–5.67) 3.27 (0.79–13.53)
Connective tissue diseases
Controls 9308 53 83.507 0.63 (0.48–0.83) reference
All eating disorders 2320 17 20.650 0.82 (0.48–1.32) 1.30 (0.75–2.24)
Anorexia nervosa 902 5 7.065 0.71 (0.23–1.65) 1.12 (0.45–2.79)
Bulimia Nervosa 1254 9 12.312 0.73 (0.33–1.39) 1.16 (0.57–2.33)
Binge Eating Disorder 164 3 1.273 2.36 (0.49–6.89) 3.71 (1.16–11.88)*
Neurological diseases
Controls 9351 19 82.858 0.23 (0.14–0.36) reference
All eating disorders 2338 6 20.450 0.29 (0.11–0.64) 1.28 (0.51–3.20)
Anorexia nervosa 910 4 7.056 0.57 (0.15–1.45) 2.47 (0.84–7.27)
Bulimia Nervosa 1257 2 12.175 0.16 (0.02–0.59) 0.72 (0.17–3.08)
Binge Eating Disorder 171 0 1.221 0 (0–3.02) 0
Hematological diseases
Controls 9361 3 82.5654 0.04 (0.008–0.11) reference
All eating disorders 2339 0 20.331 0 -
Anorexia nervosa 909 0 6.947 0 -
Bulimia Nervosa 1259 0 12.163 0 -
Binge Eating Disorder 171 0 1.221 0 -
Each participant accounted as maximum one observation per autoimmune disease category (according to the first incident autoimmune disease).Those who already
had had an autoimmune disease (Table 2) included in each category, were excluded. In the section of ‘Any autoimmune disease’, those who had had any previous
autoimmune disease were excluded. There were no incident cases in pulmonary diseases. CI, Confidence Interval; RR, Risk Ratio.
*Statistically significant P-values.
doi:10.1371/journal.pone.0104845.t003
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disordered eating, via deviant food intake and emotional stress,
impacts microbial homeostasis and modifies the composition of the
intestinal microflora [34]. In addition, purging behavior, such as
laxative abuse, may further damage intestinal mucosa and affect
gut permeability. In line, 11 new bacterial species, and 19 species
never isolated from human gut before were recently identified
from a stool sample of an AN patient [35]. Another study of the
gut bacterial composition in patients with AN revealed an increase
in methanogen M. smithii, which was suggested to be due to an
adaptive use of nutrients [36]. Not surprisingly, microbiome of AN
patients diverged from that of normal weight and obese
population. Gut microbiota is an important regulator of the
immune system and its alteration has been associated with
autoimmune diseases and immune-mediated disorders, such as
allergies and T1D [37]. Composition of the microbiota affects gut
permeability, and the function of both innate and adaptive
immune system including development of regulatory T-cells [37].
Finally, sex hormones modulate microbiota and the development
of autoimmunity [38], as well as the eating disorders risk [39]. The
interplay between gut microbiome, immune regulation, and sex
hormones thus provide one potential, complex mechanism
underlying eating disorders and explaining the partly shared
etiopathogenesis of eating disorders and autoimmune diseases.
We observed an increased risk for autoimmune endocrinolog-
ical and gastroenterological diseases among patients with eating
disorders. Suggestive increases were found also for ocular diseases,
dermatological and connective tissue diseases. These diseases
originate from different organ systems, diverse HLA genotype and
do not specifically cluster together. For example, the risk of T1D is
related to HLADQ2/DQ8 genotype, whereas Crohn’s disease
does not show HLA association, but is associated with other
immune regulation genes. Thus, the association of eating disorders
with autoimmune diseases is not explained by shared HLA related
risk but is likely to be explained by shared general immune
disturbances. Supporting the view of the importance of immune-
mediated pathways in the development of eating disorders, a
suggestive association with NCAM2 gene, which encodes protein
belonging to the immunoglobulin superfamily, was recently found
in genome-wide association analysis of AN [40]. Further
supporting the role of autoimmune processes in eating disorders,
we also observed a higher prevalence of autoimmune diseases in
men with BN compared to women; this is in line with greater load
of vulnerabilities required in males in order to develop eating
disorders [41].
The peak onset of T1D in Finland is in childhood and in
adolescence [42], and its prevalence among patients was over four-
fold at the start of the follow-up compared to control individuals.
In previous studies of eating disorders in individuals with T1D, the
association has been explained by weight gain with insulin
treatment, and subsequent body dissatisfaction combined with a
possibility to control body weight by modifying insulin dosages
[43]. Additionally, management of diabetes with strict diet,
associated hypoglycemic episodes with intense hunger, and
dysregulation of gastrointestinal hormones are recognized [43].
As discussed above, the risk of T1D in eating disorders could be
explained by shared immunologicial disturbances related to the
altered gut microbiota and dysregulated immune tolerance. It is
also possible that T1D related autoantibodies, such as glutamic
acid decarboxylase, which are also found in neurological disorders,
such as in stiff-man syndrome and in bipolar disorder [44], could
have a role in eating disorders. Supporting this, having T1D has
been shown to increase the risk for mood disorders [6].
In gastroenterological autoimmune diseases, we observed
increased period prevalence at the start of the follow-up and
increased incidence afterwards. The increase was mostly due to
Crohn’s disease, increases in celiac disease and ulcerative colitis
did not reach statistical significance. Association between Crohn’s
disease/ulcerative colitis and eating disorders has previously been
reported in individual patients [19]. It has been interpreted to base
on shifts in energy balance, demands for attention on eating, and
availability of unusual compensatory methods such as stoma or
malabsorption. However, it is possible that pro-inflammatory
cytokines activated in Crohn’s disease could contribute to the
development of eating disorders. Particularly interesting is TNF-a,
a key cytokine in Crohn’s disease, also known as cachexin due to
its strong appetite suppressing and weight loss inducing effect.
Interestingly, anecdotal evidence suggests positive effect of anti-
TNF-a treatment in Crohn’s disease on AN [45]. In celiac disease,
both brain-reactive autoantibodies as well as high prevalence of
mood disorders have been reported [3,6].
We observed significantly elevated risk of SLE in patients with
eating disorders. Its role is supported by the occurrence of brain-
reactive autoantibodies, the increased risk of SLE in mood
disorders [6], and the high rate of neuropsychiatric manifestations
in the patients with SLE [46]. The autoantibodies in Sjo¨gren’s
syndrome are also classified as brain-reactive, and the risk of mood
disorders is shown increased [6]. Anecdotal reports of the co-
occurrence of rheumatoid arthritis and AN have been published
[47]. Unfortunately, our sample was too small to draw firm
conclusions; the risk of Sjo¨gren’s syndrome, rheumatoid arthritis
and dermatological diseases were marginally increased.
Strengths and limitations
Strengths of the study include large patient cohort with eating
disorders, specifically BED, which is rare in register studies due to
its absence from diagnostic systems as an official diagnostic entity
prior DSM-5. Further strengths are long follow-up, and prospec-
tively collected register data.
Despite large sample, our study unfortunately lacked power to
detect the potential differences between patients and controls in
rare autoimmune diseases, and we observed several marginally
significant differences. Eating disorder diagnoses in our study were
admission diagnoses and did not cover co-morbidity or diagnostic
cross-overs. We neither had data of the age of eating disorder
onset. It would have also been intriguing to explore deeper the sex
differences in autoimmune diseases, but due to small number of
male patients we were unable to do so. Potential bias may arise
from more active diagnosing of autoimmune diseases in the
patients with eating disorders due to their treatment in special
health care. However, no significant differences in the evolution of
incidence rates of a composite of incident autoimmune diseases
between the patients and controls emerged, and we also observed
a higher period prevalence of autoimmune in patients before they
had entered into the treatment. Second, majority of the
autoimmune diseases studied are diagnosed in a special health
care in Finland. The treatments in hospitals are heavily subsidized
yielding low socioeconomic barriers. An important exception
relates to autoimmune thyroiditis, which is relatively common in
the population and often diagnosed and treated in primary care;
its data cannot therefore be taken fully into account. Prevalences
of other autoimmune diseases among controls were in line with
commonly described population prevalences, which further
suggest that detection bias between patients and control individ-
uals does not explain our results.
Conclusion
In conclusion, we observed the association between eating
disorders and several autoimmune diseases with different genetic
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Table 4. Lifetime prevalences of autoimmune diseases, i.e. status at the end of the study period covering the time before, during
and after the treatment for an eating disorder in patients with eating disorders compared with their control individuals.
Autoimmune disease category N (Positive/negative for the autoimmune disease, % positive) OR (95% CI) P-value
Patients Controls
Any autoimmune disease
All eating disorders 209/2133 (8.9%) 509/8859 (5.4%) 1.7 (1.5–2.0) ,0.001
Anorexia Nervosa 64/847 (7.0%) 171/3473 (4.7%) 1.5 (1.1–2.1) 0.004
Bulimia Nervosa 118/1142 (9.4%) 296/4744 (5.9%) 1.7 (1.3–2.1) ,0.001
Binge Eating Disorder 27/144 (15.8%) 42/642 (6.1%) 2.8 (1.7–4.7) ,0.001
Endocrinological diseases
All eating disorders 81/2261 (3.5%) 139/9229 (1.5%) 2.4 (1.8–3.2) ,0.001
Anorexia Nervosa 20/891 (2.2%) 57/3587 (1.6%) 1.4 (0.8–2.3) 0.2
Bulimia Nervosa 52/1208 (4.1%) 71/4969 (1.4%) 3.1 (2.1–4.5) ,0.001
Binge Eating Disorder 9/162 (5.3%) 11/673 (1.6%) 3.3 (1.4–7.9) 0.008
Gastroenterological diseases
All eating disorders 59/2283 (2.5%) 115/9253 (1.2%) 1.8 (1.4–2.5) ,0.001
Anorexia Nervosa 20/891(2.2%) 46/3598 (1.3%) 1.8 (1.03–3.0) 0.04
Bulimia Nervosa 35/1225 (2.8%) 79/4961 (1.6%) 1.8 (1.2–2.7) 0.004
Binge Eating Disorder 4/167 (2.3%) 5/679 (0.7%) 3.2 (0.86–11.9) 0.08
Ocular diseases
All eating disorders 24/2318 (1.0%) 63/9305 (0.7%) 1.5 (0.96–2.5) 0.08
Anorexia Nervosa 7/904 (0.8%) 17/3627 (0.5%) 1.7 (0.7–4.0) 0.3
Bulimia Nervosa 11/1249 (0.9%) 44/4996 (0.9%) 1.0 (0.5–2.0) 1.0
Binge Eating Disorder 6/165 (3.5%) 2/682 (0.3%) 12 (2.4–59.5) 0.002
Dermatological diseases
All eating disorders 25/2317 (1.1%) 63/9305 (0.7%) 1.6 (1.0–2.52) 0.05
Anorexia Nervosa 5/906(0.5%) 16/3628 (0.4%) 1.3 (0.5–3.4) 0.7
Bulimia Nervosa 16/1244(1.3%) 43/4997 (0.9%) 1.5 (0.8–2.6) 0.17
Binge Eating Disorder 4/167(2.3%) 4/680 (0.6%) 4.0 (1.0–16.0) 0.05
Connective tissue diseases
All eating disorders 39/2303 (1.7%) 113/9255 (1.2%) 1.4 (0.96–2.0) 0.08
Anorexia Nervosa 14/897 (1.5%) 30/3614 (0.8%) 1.9 (1.0–3.5) 0.05
Bulimia Nervosa 15/1245(1.2%) 61/4979 (1.2%) 1.0 (0.5–1.8) 0.9
Binge Eating Disorder 10/161 (5.8%) 22/662 (3.2%) 1.8 (0.8–4.0) 0.11
Neurological diseases
All eating disorders 10/2332 (0.4%) 36/9332 (0.4%) 1.1 (0.5–2.2) 0.8
Anorexia Nervosa 5/906 (%) 10/3634 (0.3%) 2.0 (0.7–5.9) 0.2
Bulimia Nervosa 5/1255 (0.4%) 24/5016 (%) 0.8 (0.3–2.2) 0.7
Binge Eating Disorder 0/171 2/682 (0.3%) - -
Hematological diseases
All eating disorders 3/2339 (0.1%) 10/9358 (0.1%) 1.2 (0.3–4.4) 0.78
Anorexia Nervosa 2/909 (0.2%) 2/3642 (0.05%) 4.0 (0.6–28.4) 0.17
Bulimia Nervosa 1/1259 (0.08%) 8/5032 (0.2%) 0.5 (0.1–4.0) 0.5
Binge Eating Disorder 0/171 0/684 - -
Pulmonary diseases
All eating disorders 1/2341 (0.04%) 0/9368 - -
Anorexia Nervosa 0/911 0/3644 - -
Bulimia Nervosa 1/1259 0/5040 - -
Binge Eating Disorder 0/171 0/684 - -
doi:10.1371/journal.pone.0104845.t004
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backgrounds. Our data support the findings from other studies
indicating the role of immunological mechanisms at least in a
subpopulation of patients with eating disorders. We recommend
that clinicians treating patients with eating disorders consider the
increased risk of autoimmune diseases and the possible role of
autoimmune processes underlying these individuals’ somatic and
neuropsychiatric symptoms related to mood disturbances, anxiety
and disordered eating. Future studies are needed to explore the
risk of autoimmune diseases and the immunological mechanisms
in individuals with various eating disorders and their family
members.
Table 5. Autoimmune disease status per each individual autoimmune disease included in the study at the end of the study period
(covering the time before, during and after the treatment) for a composite of all patients with eating disorder compared with their
control individuals.
Autoimmune disease category
N (Positive/negative for the autoimmune
disorder, % positive) OR (95% CI) P-value
Patients Controls
Endocrinological diseases
Type I diabetes mellitus 68/2274 (2.9%) 76/9292 (0.8%) 3.79 (2.70–5.31) ,0.001
Autoimmune hyperthyroidism (Basedow’s disease, Grave’s disease) 13/2329 (0.6%) 56/9312 (0.6%) 0.93 (0.51–1.7) 0.81
Autoimmune thyroiditis (Hashimoto’s disease) 2/2340 (0.09%) 9/9359 (0.1%) 0.89 (0.19–4.11) 0.88
Adrenal insufficiency (Addison’s disease) 1/2341 (0.04%) 0/9368 - -
Gastroenterological diseases
Celiac disease 16/2326 (0.7%) 44/9324 (0.5%) 1.45 (0.82–2.58) 0.2
Regional enteritis (Crohn’s disease) 27/2315 (1.1%) 35/9333 (0.4%) 3.09 (1.87–5.10) ,0.001
Ulcerative colitis 24/2318 (1.0%) 69/9299 (0.7%) 1.4 (0.88–2.24) 0.16
Primary biliary cirrhosis 0/2342 2/9366 (0.02%) - -
Ocular diseases
Iridocyclitis 24/2318 (1.0%) 63/9305 (0.7%) 1.54 (0.96–2.47) 0.08
Dermatological diseases
Pemphigus/pemphigoid 1/2341 (0.04%) 3/9365 (0.03%) 1.33 (0.14–12.8) 0.8
Dermatitis herpetiformis (skin condition associated with celiac
disease)
0/2342 0/9368 - -
Psoriasis 22/2320 (0.9%) 56/9312 (0.6%) 1.57 (0.96–2.57) 0.07
Vitiligo 1/2341 (0.04%) 3/9365 (0.03%) 1.33 (0.14–12.8) 0.8
Lupus Erythematosus Discoides (LED) 1/2342 (0.04%) 1/9367 (0.01%) 4.0 (0.25–64.0) 0.33
Connective tissue diseases
Rheumatoid arthritis 15/2327 (0.6%) 45/9323 (0.5%) 1.33 (0.74–2.39) 0.33
Arthritis rheumatoides juvenilis 11/2331 (0.5%) 34/9334 (0.4%) 1.29 (0.66–2.55) 0.46
Ankylosing spondylitis 7/2335 (0.3%) 30/9338 (0.3%) 0.93 (0.41–2.12) 0.87
Polymyositis/Dermatomyositis 1/2341 (0.04%) 4/9364 (0.04%) 1.0 (0.11–8.95) 1.00
Systemic lupus erythematosus (SLE) 6/2336 (0.3%) 6/9362 (0.06%) 4.0 (1.29–12.4) 0.02
Systemic scleroderma 1/2341 (0.04%) 2/9366 (0.02%) 2.0 (0.18–22.1) 0.57
Mixed Connective Tissue Disease (MCTD) 2/2340 (0.09%) 2/9366 (0.02%) 4.0 (0.56–28.4) 0.17
Sjo¨gren’s syndrome 9/2333 (0.4%) 17/9351 (0.2%) 2.12 (0.94–4.75) 0.07
Sarcoidosis 0/2342 2/9366 (0.02%) - -
Vasculitides 2/2340 (0.09%) 4/9364 (0.04%) 2.0 (0.37–10.90) 0.42
Neurological diseases
Multiple sclerosis 8/2334 (0.3%) 31/9337 (0.3%) 1.03 (0.48–2.25) 0.94
Myasthenia gravis 2/2340 5/9363 (0.05%) 1.6 (0.31–8.25) 0.57
Hematological diseases
Autoimmune hemolytic anemia 2/2340 (0.09%) 1/9367 (0.01%) 8.0 (0.73–88.20) 0.09
Idiopathic thrombocytopenic purpura (ITP) 0 6/9362 (0.06%) - -
Pernicious anemia 1/2341 (0.04%) 3/9365 (0.03%) 1.33 (0.14–12.8) 0.8
Pulmonary diseases
Idiopathic fibrosing alveolitis 1/2341 (0.04%) 0/9368 - -
Odds Ratios (OR) are presented if meaningful analyses were possible.
doi:10.1371/journal.pone.0104845.t005
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